Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Unknown 5Recruiting 5Not yet recruiting 3Completed 2Active not recruiting 2Terminated 1

Sponsor Class

OTHER 75INDUSTRY 47NIH 10OTHER_GOV 2NETWORK 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 10Stomach Neoplasms 8Prostatic Neoplasms 6Ovarian Neoplasms 5Neoplasms 4Lung Neoplasms 4Colorectal Neoplasms 4Carcinoma, Ovarian Epithelial 4Endometrial Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Triple Negative Breast Neoplasms 2Thyroid Neoplasms 2Lymphoma, Follicular 2Fallopian Tube Neoplasms 2COVID-19 2Breast Cancer Lymphedema 2Anxiety Disorders 2Adenoma 2Uveitis 1Uterine Cervical Dysplasia 1Stress, Psychological 1Stomatitis 1Skin Neoplasms 1Scleritis 1Renal Insufficiency, Chronic 1Radiation Injuries 1Pulmonary Disease, Chronic Obstructive 1Progression-Free Survival 1Ovarian, Fallopian, and Primary Peritoneal Cancer 1Operable Breast Cancer 1

Interventions

atezolizumab 1Capecitabine 1CP protocol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × OTHER_GOV × Triple Negative Breast Neoplasms × Clear all
NCT03756298 2026-04-23

Efficacy and Safety of Atezolizumab Plus Capecitabine Adjuvant Therapy for Triple Receptor-Negative Breast Cancer

National Cancer Center, Korea

Phase 2 Active not recruiting
284 enrolled
Breast

Triple Negative Breast Neoplasms

NCT03168880 2025-04-09

TNBC

Tata Memorial Hospital

Phase 3 Active not recruiting
720 enrolled
Breast

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡